Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations

On April 30, 2026 Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, reported that two latest clinical study results of its novel Nectin‑4 targeting ADC (R&D code: 9MW2821) in cervical cancer will be presented respectively as an oral presentation and a poster presentation, at the 2026 European Society for Medical Oncology Gynaecological Cancers (ESMO GC) Annual Congress in Copenhagen, Denmark, June 17–19, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral Presentation

Title:
Bulumtatug Fuvedotin (BFv, 9MW2821), a nectin-4 antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: Updated results from a phase I/II study.
Abstract No.: 28RO
Presenter: Prof. Yang Huijuan, Fudan University Shanghai Cancer Center
Session Date and Time: 6/17/2026 2:45PM-4:10PM (local time)

Poster Presentation

Title:
Preliminary results of Bulumtatug Fuvedotin (BFv, 9MW2821) in combined with Toripalimab in patients with recurrent or metastatic cervical cancer: A cohort from a Phase Ib/II Clinical Study.

Abstract No.: 36P
Principal Investigator:
Prof. Lou Hanmei, Zhejiang Cancer Hospital
Prof. Wang Yudong, International Peace Maternity and Child Health Hospital of China Welfare Institute
Session Date and Time: 6/18/2026 12:45PM-1:30PM (local time)

(Press release, Mabwell Biotech, APR 30, 2026, View Source;mabwell-to-present-latest-clinical-data-on-9mw2821-for-cervical-cancer-in-oral-and-poster-presentations-302758286.html [SID1234664984])

Factor Bioscience to Showcase Engineered iMacrophages (FACT-112) Targeting Ovarian Cancer In Vivo at ISCT 2026

On April 30, 2026 Factor Bioscience Inc., a Cambridge-based biotechnology company focused on using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported its participation in the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting to be held in Dublin, Ireland from May 6-9, 2026. Factor will deliver an oral presentation on FACT-112, Factor’s IL12-expressing iMacrophage program for solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to share the latest pre-clinical data from our FACT-112 program at ISCT," said Dr. Matt Angel, Co-Founder, Chairman and CEO of Factor. "The striking anti-tumor activity of our engineered iMacrophages, demonstrated in vivo, represents a major milestone for the company, underscoring our commitment to translating cutting-edge science into clinically meaningful therapies."

Factor’s Associate Director of Cell Engineering, Ian Hay, who will deliver the presentation, added, "these data illustrate the intrinsic capacity of IL12-expressing iMacrophages to repolarize the immunosuppressive ovarian tumor microenvironment and elicit immune-mediated tumor rejection. We are excited about the potential to develop FACT-112 into a safe, effective option to patients with solid tumors."

Details of the oral presentation are below:

"iPSC-Derived Macrophages Engineered to Express IL-12 Modulate the Tumor Microenvironment and Support T Cell Lysis of Ovarian Cancer Models" -to be presented by Ian Hay on Wednesday, May 6 from 1:00-2:00 pm GMT, in the Immunotherapy Oral Presentation Session.

For more information about the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, visit www.isctglobal.org/annual-meeting.

(Press release, Factor Bioscience, APR 30, 2026, View Source [SID1234664983])

Huahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug HH160

On April 30, 2026 Huahui Health reported that it has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a novel trispecific antibody in oncology immunotherapy. Under the agreement, BeOne Medicines is granted an exclusive option covering the development, manufacturing, and commercialization of HH160 worldwide.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the agreement, BeOne Medicines will pay Huahui Health an upfront payment of USD 20 million. Upon exercise of the option by BeOne Medicines, Huahui Health will be entitled to receive an additional USD 100 million option exercise payment. Subject to the achievement of development, regulatory and sales milestones, Huahui Health is eligible to receive milestone payments of up to USD 1.9 billion in milestone payments, as well as tiered royalties on net sales. The parties have also agreed to maintain discussions regarding BeOne Medicines’ potential participation in Huahui Health’s future financing activities, with specific transaction terms and details to be negotiated separately.

Dr. Chen Bin, CEO of Huahui Health, stated, "Huahui Health has established an integrated research and development engine covering the full drug development value chain, enabling the independent identification of novel targets and development of proprietary drug candidates. Our pipeline includes one marketed product and several clinical-stage programs in Phase II, reflecting strong industry recognition of our R&D capabilities. BeOne Medicines is distinguished by its outstanding innovation capacity and global development expertise. We are delighted to deepen our collaboration with BeOne Medicines to advance HH160, a novel trispecific antibody for cancer immunotherapy, and to bring innovative immuno-oncology treatments to patients worldwide as early as possible."

In January 2026, China’s NMPA granted conditional approval to Libevitug injection, Huahui Health’s first commercial product, for chronic hepatitis D infection in adults with or without compensated cirrhosis. As a human monoclonal antibody targeting the PreS1 domain of HBV and HDV envelope protein, it blocks viral entry into hepatocytes. A pioneering first-in-class antibody for viral hepatitis and China’s first approved HDV therapy, Libevitug fills a critical unmet clinical gap. It received Breakthrough Therapy Designation from both NMPA and FDA, with its global Phase III trial now underway.

Going forward, Huahui Health will leverage its robust in-house innovation platforms and full-chain R&D strengths to advance first-in-class and best-in-class candidates across liver diseases and oncology. Backed by a rich layered pipeline spanning preclinical to clinical stages, the company demonstrates outstanding independent innovation and sustainable capacity to deliver original novel drugs worldwide.

About HH160

HH160 is a novel trispecific antibody developed by Huahui Health using its proprietary PolyBoost multispecific antibody platform. HH160 simultaneously targets PD-1, CTLA-4, and VEGF-A, three clinically validated targets in cancer immunotherapy and anti-angiogenesis. Through its "three-in-one" synergistic mechanism of action, HH160 is expected to enhance therapeutic efficacy, achieve tumor-specific drug distribution, and reduce treatment-related adverse effects. Positive preclinical results for HH160 were presented at the 2025 Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) held in Chicago, United States.

(Press release, Huahui Health, APR 30, 2026, View Source [SID1234664982])

IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program

On April 30, 2026 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, reported that the U.S. Food and Drug Administration (FDA) has agreed to review its New Drug Application (NDA) for darovasertib in combination with crizotinib (darovasertib combination) for patients with first line (1L) HLA*A2-negative metastatic uveal melanoma (mUM) under the Oncology Center of Excellence (OCE) Real-Time Oncology Review (RTOR) program.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are grateful for the continued partnership with the FDA and being accepted in the Oncology Center of Excellence Real-Time Oncology Review program based on the topline results from the OptimUM-02 trial. This is an important achievement for IDEAYA and the people living with mUM who today have very few treatment options. We believe the topline results from OptimUM-02 provide further evidence to support the potential benefit of the darovasertib combination in patients with first-line HLA*A2-negative mUM, and we look forward to working closely with the FDA through the RTOR process to make this promising new potential treatment available to patients as quickly as possible," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.

On April 13th, IDEAYA reported positive topline data from the Phase 2/3 OptimUM-02 trial of darovasertib in combination with crizotinib in 1L HLA*A2-negative mUM. The trial met its primary endpoint, with the combination reducing the risk of disease progression by 58% (Hazard Ratio of 0.42; 95% CI: 0.30, 0.59; p-value: <0.0001) and achieving a statistically significant improvement in median progression-free survival (PFS) of 6.9 months versus 3.1 months in the investigator choice of therapy (ICT) arm as assessed by blinded independent central review (BICR). On secondary endpoints, an overall response rate (ORR) of 37.1%, including 5 complete responses, was observed in patients treated with the darovasertib combination versus 5.8% in the ICT arm (p-value: <0.0001) with a median duration of response (DOR) of 6.8 months. Overall survival (OS) data were not yet mature, however the darovasertib combination did show an early trend in OS improvement versus the ICT arm. The combination was generally well-tolerated with a manageable safety profile consistent with previously reported results and known side-effects of each drug.

The FDA’s OCE RTOR program allows an applicant to pre-submit components of its NDA to allow the FDA to review clinical trial data before the complete filing is submitted and aims to provide a more efficient review process to ensure safe and effective treatments are available to patients as early as possible. IDEAYA plans to initiate the RTOR submission process with the first pre-submission targeted for May, with completion of the NDA filing expected in the second half of 2026.

Full results from the OptimUM-02 trial will be presented in a late-breaking oral presentation at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting, taking place in Chicago, Illinois. IDEAYA is also conducting clinical trials of darovasertib in HLA*A2-positive mUM as well as in the neoadjuvant and adjuvant settings of primary uveal melanoma.

(Press release, Ideaya Biosciences, APR 30, 2026, View Source [SID1234664981])

TLX101-Px (Pixlumi®) MAA Accepted in Europe

On April 30, 2026 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") reported that the marketing authorization application (MAA) filed in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer) imaging candidate[1], has been validated and accepted for review.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The application, covering commercially significant European markets[2], has now moved into a 210-day active assessment phase[3]. Telix is seeking to expand patient access to advanced brain imaging through a broad clinical label, reflective of current clinical practice guidelines[4]. Assuming a positive outcome from the application at Day 210, national marketing authorizations are expected to follow shortly after.

In Europe, there is currently no generally available commercial product for PET[5] imaging of glioma with 18F-FET ("FET-PET"), resulting in an acute and immediate need for a consistent, high-quality product [6]. Through this MAA, Telix aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications. TLX101-Px is also being developed as a patient selection and response assessment tool for Telix’s glioblastoma therapy candidate TLX101-Tx (iodofalan 131I), which has been granted orphan drug designation in Europe and the U.S. The Phase 3 IPAX-BrIGHT[7] trial of TLX101-Tx in patients with recurrent glioblastoma has commenced patient dosing internationally[8] and is launching in multiple European countries.

Sied Kebir, MD, Head of Clinical Neuro-Oncology, University Hospital Essen, said: "In our day-to-day practice, one of the hardest questions we face is whether a change on conventional imaging reflects tumor progression or a treatment-related effect. PET imaging with ¹⁸F-FET can be used to help resolve this dilemma. The acceptance of this application is a welcome step toward broader, standardized patient access across Europe, and more timely and accurate decision-making."

Raphaël Ortiz, Chief Executive Officer, Telix International, commented, "The acceptance of our European MAA represents a significant regulatory milestone for Telix and for TLX101‑Px. It supports a critical unmet need for widely accessible glioma imaging for both diagnostic evaluation and therapeutic decision‑making. Subject to regulatory approval, we are preparing to bring this powerful precision medicine product to market in both Europe and the United States, where our new drug application has recently been accepted[9]."

About glioma in Europe

In Europe, approximately 67,500 brain and central nervous system tumors are diagnosed every year[10], with gliomas accounting for approximately 30% of these, and up to 80% of all malignant brain tumors[11]. There is a critical unmet need to improve the diagnosis and management of gliomas, which are the most common primary brain tumors of the central nervous system, particularly in the post-treatment setting4. Conventional MRI imaging techniques have several limitations, including a lack of biological specificity, dependency on blood-brain barrier disruption, and an inherent inability to differentiate between tumor progression or treatment-related causes. This can yield inconclusive results and delay time-sensitive treatment decisions[12]. With low survival rates and the need to make rapid decisions, precision imaging is paramount6. Subject to regulatory approval, TLX101-Px has the potential to address this need, enabling patients in Europe and worldwide to receive greater clarity in their diagnosis and treatment decision making.

About TLX101-Px

TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine) is Telix’s PET imaging candidate for the characterization of glioma. TLX101-Px targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). This enables TLX101-Px to be potentially utilized as a patient selection and response assessment tool for TLX101-Tx (iodofalan 131I), Telix’s LAT1-targeting glioblastoma (GBM) therapy candidate, currently under investigation in Telix’s IPAX-2[13] and IPAX-BrIGHT studies. TLX101-Px and TLX101-Tx have not received marketing authorizations in any jurisdiction. In relevant European markets, the proposed brand name for TLX101-Px is "Pixlumi". Brand name and commercial launch are subject to final regulatory approval.

(Press release, Telix Pharmaceuticals, APR 30, 2026, View Source [SID1234664980])